跳至主要内容
临床试验/NCT00502775
NCT00502775已完成4 期

A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis

GlaxoSmithKline43 个研究点 分布在 1 个国家目标入组 680 人开始时间: 2007年8月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
680
试验地点
43
主要终点
Mean Change From Baseline in the Nighttime Symptom Score (NSS)

研究概览

简要总结

The primary objective of the study is to compare nighttime symptom relief of fluticasone furoate nasal spray versus oral fexofenadine

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed consent
  • Otherwise healthy outpatient with mountain cedar allergy
  • Male or eligible female Females of childbearing potential must commit to the consistent and correct use of an acceptable method of birth control
  • Age 12 years or older at Visit 2
  • Diagnosis of seasonal allergic rhinitis (SAR) to mountain cedar
  • Adequate exposure to mountain cedar pollen
  • Ability to comply with study procedures

排除标准

  • Significant concomitant medical conditions
  • Use of intranasal corticosteroids within four weeks prior to Visit 1; use of inhaled, oral, intramuscular, intravenous, ocular, and/or dermatological corticosteroid (with the exception of hydrocortisone cream/ointment, 1% or less) within eight weeks prior to Visit
  • Use of other allergy medications within specific timeframes relative to Visit 1
  • Use of other medications that may affect allergic rhinitis or its symptoms
  • Use of immunosuppressive medications eight weeks prior to screening and during the study
  • Immunotherapy patients who are not stable on current dose
  • Use of any medications that significantly alters the pharmacokinetics of fluticasone furoate or fexofenadine
  • Allergy/Intolerance to corticosteroids, antihistamines, or any excipients in the two products
  • Use of contact lenses
  • Recent clinical trial/experimental medication experience within 30 days of Visit 1
  • Subject previously failed the 21-day screen period or failed to complete the treatment period
  • Positive or inconclusive pregnancy test or female who is breastfeeding
  • Employee or relative affiliation with investigational site
  • Current tobacco use
  • Active chickenpox or measles or exposure in the last 3 weeks

结局指标

主要结局

Mean Change From Baseline in the Nighttime Symptom Score (NSS)

时间窗: Baseline and Weeks 1-2

Questions include: 1. Nasal congestion on awakening (Score: 0=none, 1=mild, 2=moderate, 3=severe); 2. Difficulty going to sleep (Score: 0=not at all, 1=little, 2=moderately, 3=very); 3. Nighttime awakenings (Score: 0=not at all, 1=once, 2=more than once, 3=felt like awake all night). The sum of the ratings for the three items comprises the NSS.

次要结局

  • Mean Change From Baseline in Daytime Reflective Total Nasal Symptom Score (D-rTNSS)(Baseline and Weeks 1-2)
  • Mean Change From Baseline in Pre-Dose Instantaneous Total Nasal Symptom Score (iTNSS)(Baseline and Weeks 1-2)
  • Mean Change From Baseline in Daytime Reflective Total Ocular Symptom Score (D-rTOSS)(Baseline and Weeks 1-2)
  • Mean Change From Baseline in 24 Hour Reflective Total Ocular Symptoms Score (rTOSS)(Baseline and Weeks 1-2)
  • Mean Change From Baseline in Morning Peak Nasal Inspiratory Flow (PNIF)(Baseline and Weeks 1-2)
  • Mean Change From Baseline in Nighttime Reflective Total Nasal Symptom Score (N-rTNSS)(Baseline and Weeks 1-2)
  • Mean Change From Baseline in Nighttime Reflective Total Ocular Symptom Score (N-rTOSS)(Baseline and Weeks 1-2)
  • Mean Change From Baseline in Evening Peak Nasal Inspiratory Flow (PNIF)(Baseline and Weeks 1-2)
  • Mean Change From Baseline at Day 15 for Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)(Baseline, Day 15 or if Early Withdrawal Day)
  • Mean Change From Baseline in 24 Hour Reflective Total Nasal Symptom Score (24 Hour rTNSS)(Baseline and Weeks 1-2)
  • Mean Change From Baseline in Pre-Dose Instantaneous Total Ocular Symptom Score (iTOSS)(Baseline and Weeks 1-2)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (43)

Loading locations...

相似试验